Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
oNKord in AML complete remission with measurable residual disease
NL-OMON52744Phase 1Recruiting
- Sponsor
- Glycostem Therapeutics
- Start
- Nov 2020
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of oNKord in acute myeloid leukemia (AML) (6 cohorts), sponsored by Glycostem Therapeutics. Primary endpoints: Safety and tolerability and Cumulative incidence of measurable residual disease response. Started Nov 2020; status: recruiting.
02
Drugs
oNKord
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON52744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52744.